KOLOA, Hawaii — When deciding which patients with diabetic retinopathy to treat with anti-VEGFs, ophthalmologists should consider severity of disease, according to a speaker here.
During a presentation at Retina 2023, Roger A. Goldberg, MD, said that regression of DR induced by anti-VEGF treatment is unique in mild or moderate nonproliferative DR (NPDR).
“It's really regression in name only. It turns out that induced mild or moderate NPDR doesn't really behave like native, untreated mild or moderate NPDR,” Goldberg said. “The induced, improved DR is much more volatile